PharmaVitae 2005: Schering AG Global and US Analysis
Price:
$5 700.00
Introduction
This analysis examines the market position and future outlook for Schering AG, encompassing global and US company strategy, portfolio and pipeline analysis and assessment of financial performance, with global, US and ROW forecasts for key drugs to 2010. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information
Reasons to Purchase
Evaluate the level of risk involved in Schering’s R&D dependence following recent setbacks to promising pipeline products, particularly PTK/ZK
Benchmark Schering AG’s performance against key rivals in the ethical pharmaceutical sector
Evaluate the threats faced by Schering’s different franchises, particularly Women’s Health, over the forecast period
